Bone drug can improve breast cancer disease-free survival

New research claims to show the addition of zoledronic acid to endocrine therapy can help improve the disease-free survival rates of early stage breast cancer in premenopausal women.

Research centres in Austria and Germany found the acid, normally used in bone treatments, has a positive effect on estrogen-responsive breast cancer.

They studied 1,803 menopausal women with early stage endocrine-responsive breast cancer and assigned them to receive treatment with or without zoledronic acid over a three year period.

It was found the addition of zoledronic acid did not significantly reduce the risk of death and no unexpected adverse events were found.

"The addition of zoledronic acid to adjuvant endocrine therapy improves disease-free survival in premenopausal patients with estrogen-responsive early breast cancer," concluded the study authors.

A recent study by the Fred Hutchinson Cancer Research Centre found the long-term use of multivitamins does not impact on the risk of cancers in postmenopausal women.